The Hemophilia Center

What The Hemophilia Center does

The Hemophilia Center of Western Pennsylvania (HCWP) is a 501(c)(3) nonprofit charitable organization incorporated in 1972 in Pittsburgh, Pennsylvania, and one of the first centers included in the federally funded national network of Hemophilia Treatment Centers established in 1975. It delivers comprehensive multidisciplinary care to children and adults with hemophilia, von Willebrand disease (VWD), and other inherited bleeding and clotting disorders (including hemoglobinopathies and thrombophilia), serving patients across Western Pennsylvania through its main Pittsburgh clinic and three annual regional outreach clinics. The care model is built around an annual comprehensive evaluation by a coordinated team of physicians, nurses, physical therapists, social workers, genetic counselors, and pharmacists.

HCWP's clinical product portfolio comprises five core service lines: a Factor Program operating under the federal 340B Drug Pricing Program and routed through the closed-door contract pharmacy CanyonCareRx (which handles 24-48 hour standard delivery plus same-day courier); Genetic Counseling for family-history documentation, testing coordination, and reproductive planning; Nursing services including home-infusion training and yearly multidisciplinary evaluations; Physical Therapy featuring point-of-care diagnostic musculoskeletal ultrasound; and Social Work for psychosocial support, insurance navigation, and Camp Hot-to-Clot leadership. Digital patient-facing tools include an online factor ordering portal that supports all major clotting-factor brands and a secure document-upload portal accepting PDF, JPG, and PNG files. The center also maintains a long-running research program that participates in ATHN national registry studies (ATHN 9, 10, 11, Serological Surveillance, PoP Profile), NIH-funded work, and pharmaceutical-sponsored Phase I-IV trials including Spark Therapeutics gene therapy studies (SPK-8011-101 and SPK-8016).

Revenue derives from a combination of 340B drug-pricing program spreads, insurance reimbursement (Medicare, UPMC Health Plan, Highmark BCBS, Highmark Wholecare, UPMC for You, Gateway Health, and BCBS Anthem plans), federal and state HTC grants, and clinical research fees. Distribution is geographically concentrated within Western Pennsylvania with no disclosed expansion beyond the region. The organization is governed by a board of directors rather than shareholders, with no outside equity holders; leadership transitioned in October 2025 with Ed Smith appointed Executive Director, supported by Clinical Directors for adult and pediatric services and a Director of Operations.

Name

The Hemophilia Center

Legal name

Hemophilia Center of Western Pennsylvania

Website

https://hcwp.vitalant.org

Company type

Private

Founded year

1972

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

The Hemophilia Center of Western Pennsylvania is a 501(c)(3) nonprofit, federally designated Hemophilia Treatment Center providing comprehensive multidisciplinary care to children and adults with hemophilia, von Willebrand disease, and other inherited bleeding and clotting disorders across Western Pennsylvania.

Ownership category

akta.pro rank

Product category

Hemophilia Treatment Services

NAICS

Ambulatory Health Care Services (621), Home Health Care Services (62161)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro industry

PRIMARYHLAKAFAA

Medical Hematology (Benign Hematology)

Healthcare & Life Sciences/Specialist Medical Practice/Hematology & Oncology

SECONDARYHLAKAFAE

Pediatric Hematology & Oncology

Healthcare & Life Sciences/Specialist Medical Practice/Hematology & Oncology

SECONDARYHLAIACAI

Hematology Specialty Pharmaceuticals (Non-malignant)

Healthcare & Life Sciences/Pharmaceuticals/Specialty Pharmaceuticals

Keywords

• Hemophilia treatment services
• Bleeding disorder care
• Factor replacement therapy
• Genetic counseling services
• Clinical research trials

Headquarters

HQ city

Scottsdale

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. 340B Drug Pricing Program: HCWP participates in the federal 340B Drug Pricing Program, purchasing clotting factor at discounted Public Health Service rates. The program income supports patient care and related services necessary to provide comprehensive treatment. The center operates its factor program through contract pharmacy CanyonCareRx.
2. Patient Care Services: Comprehensive medical care services including annual evaluations, coagulation evaluation, clotting factor infusions, laboratory testing, physical therapy, genetic counseling, and psychosocial services. Funded through a combination of insurance reimbursement and federal/state support.
3. Clinical Research: HCWP participates in pharmaceutical-sponsored research trials (Phase I-IV), NIH-funded research, and gene therapy studies. Research activities include observational studies, clinical drug trials, and registry studies through partnerships with organizations like ATHN and Spark Therapeutics.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

The Hemophilia Center of Western Pennsylvania (HCWP) is a federally designated Hemophilia Treatment Center that provides comprehensive, multidisciplinary medical care to residents living with hemophilia, von Willebrand disease, and other inherited bleeding and clotting disorders. Core delivery includes factor replacement therapy dispensed through the federal 340B Drug Pricing Program (via contract pharmacy CanyonCareRx), supported by genetic counseling, nursing, physical therapy with point-of-care ultrasound, social work, and psychosocial services. The portfolio is rounded out by clinical research programs spanning gene therapy trials, Phase I-IV drug studies, and observational registries.

Product overview

The Hemophilia Center of Western Pennsylvania is a comprehensive hemophilia treatment center offering a coordinated portfolio of clinical services centered on its Factor Program. The core offering includes factor replacement therapy through the 340B Drug Pricing Program, supported by CanyonCareRx as its contract pharmacy. Clinical services span genetic counseling, nursing care, physical therapy, and social work—all delivered through a multidisciplinary team during annual comprehensive evaluations. Patient-facing digital services include an Online Factor Ordering portal and Patient File Upload system. The Center also maintains an active research program encompassing gene therapy studies, clinical drug trials, and observational registries.

Differentiator

Problem solved

Functional benefit

Products and services

• Factor Program Comprehensive clotting factor program that provides factor replacement products to hemophilia patients, operating through the federal 340B Drug Pricing Program to offer discounted medications and expanded patient services.
• Genetic Counseling Genetic counseling services that document family history, provide education about genetics of bleeding/clotting disorders, discuss and coordinate genetic testing options, and review test results for patients and families.
• Nursing Services Comprehensive nursing care including yearly evaluations by multidisciplinary teams, medical history review, physical exams, home infusion training, and coordination of care between medical professionals.
• Physical Therapy Physical therapy services for joint and muscle bleeds including point of care ultrasounds, home exercise programs, pain management, supportive devices, and collaboration with school and rehabilitation professionals.
• Social Work Services Psychosocial support services including needs assessment, patient education, advocacy, school in-services, medical jewelry ordering, and referrals to specialists, counselors, and financial assistance programs.
• Online Factor Ordering Online portal for ordering factor products and home treatment supplies including syringes, needles, gauze, sharps containers, gloves, and other infusion supplies.
• Patient File Upload Secure document submission portal for patients to upload medical files, supporting PDF, JPG, and PNG formats.
• CanyonCareRx Contract Pharmacy Closed-door contract pharmacy providing clotting factor products to existing HCWP patients, operating for over 7 years as the Center's pharmacy provider with 24-48 hour delivery and same-day courier for emergencies.
• Research Studies and Clinical Trials Comprehensive research program including gene therapy studies, clinical drug trials (Phase I-IV), non-drug observational studies, and registry/repository studies spanning over 30 years of research experience.
• Annual Comprehensive Evaluations Multidisciplinary annual evaluations bringing together physicians, nurses, physical therapists, social workers, and genetic counselors to provide comprehensive care planning for patients with hemophilia, VWD, and other inherited bleeding disorders.

Quantifiable outcome

• Mean patient satisfaction score of 3.7 out of 4.0 (YTD)

Named customers3 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• CanyonCareRxcoreChannel Partner/ Reseller/ DistributorContract pharmacy provider for HCWP's clotting factor program for over 7 years. CanyonCareRx is a closed-door pharmacy serving existing HCWP patients, providing factor delivery, supplies, and 24/7 on-call services. HCWP's factor program was established in 2000 and operates through CanyonCareRx under the federal 340B Drug Pricing Program.
• Western Pennsylvania Chapter of the National Hemophilia FoundationcoreStrategic or Co-development PartnerLocal chapter partnership supported through HCWP's 340B program income. HCWP provides educational, insurance, and research support to benefit the bleeding disorder community through this partnership.
• American Thrombosis and Hemostasis Network (ATHN)coreStrategic or Co-development PartnerHCWP participates in ATHN's national registry studies including the ATHN Dataset, ATHN Serological Surveillance Study, ATHN 9, ATHN 10, ATHN 11 studies, and ATHN PoP Profile Study. ATHN coordinates national hemophilia treatment center data and offers free genotyping for rare coagulation disorders.
• Foundation for Women & Girls with Blood DisordersminorStrategic or Co-development PartnerOrganization supported through HCWP's 340B program income to benefit the hemophilia community, specifically addressing care for women and girls with blood disorders who have historically been under-recognized in the field.
• World Federation of HemophiliaminorStrategic or Co-development PartnerInternational organization supported through HCWP's 340B program income to advance hemophilia care and treatment globally.
• Patient Services Inc.minorStrategic or Co-development PartnerPatient assistance organization supported through HCWP's 340B program income, providing insurance and financial support resources for the bleeding disorder community.
• University of Pittsburgh Vascular Medicine InstituteminorStrategic or Co-development PartnerAcademic research partnership supported through HCWP's 340B program income, collaborating on bleeding disorder research and treatment advancement.
• Spark TherapeuticscoreOthersSponsor of gene therapy clinical trials including SPK-8011-101 (gene-transfer study for hemophilia A) and SPK-8016 dose-finding study (for individuals with FVIII inhibitors). Spark Therapeutics provides funding for investigational gene therapy drug studies conducted at HCWP.

Scale indicators5 records

Recent moves9 records

Expansion highlights5 records

Others

• National Hemophilia Foundation: National advocacy and education organization for the bleeding disorders community; not a direct care provider but the umbrella entity for the Western PA chapter HCWP partners with, setting clinical guidelines and influencing federal HTC funding.
• Hemophilia Federation of America: National patient advocacy organization serving the bleeding disorders community with education, insurance resources, and policy advocacy. Adjacent ecosystem player that complements but does not compete with HCWP.

Direct peers

• Gulf States Hemophilia and Thrombosis Center: Texas Children's Hospital-based federally funded HTC providing comprehensive hemophilia and thrombophilia care across the Gulf region. Comparable multidisciplinary model including factor dispensing, clinical trials, and outreach clinics.
• Children's Hospital Los Angeles Hemophilia Treatment Center: Federally funded HTC operating within CHLA's pediatric hematology program, providing comprehensive bleeding disorder care and clinical trials. Pediatric-focused structural peer to HCWP's pediatric service line led by Dr. Xavier.
• Bleeding & Clotting Disorders Institute: An independent non-profit HTC in Peoria, Illinois providing comprehensive hemophilia, VWD, and thrombophilia care with a 340B factor program and clinical research portfolio. Closely comparable in size, structure, and regional scope to HCWP.
• New England Hemophilia Treatment Center at Boston Children's Hospital: Major pediatric HTC within Boston Children's providing comprehensive hemophilia care, factor programs, and clinical research. Comparable federally designated HTC offering multidisciplinary services across a similar patient population.
• Indiana Hemophilia & Thrombosis Center: A large, independent non-profit Hemophilia Treatment Center in Indianapolis delivering comprehensive multidisciplinary bleeding disorder care under a similar 340B-plus-clinical-research model. Operates at greater scale than HCWP but with structurally comparable services (factor program, hematology, PT, social work, genetic counseling, clinical trials).
• Mountain States Regional Hemophilia and Thrombosis Center: University of Colorado-affiliated HTC serving the Mountain West region with multidisciplinary hematology care, 340B factor dispensing, and clinical research. Comparable operating model to HCWP but anchored in a larger academic medical center.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/vitalantorg

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Hemophilia Center